The drug misoprostol provides a safe, convenient, and inexpensive means to prevent postpartum hemorrhage, a major killer of women in developing countries. The study was conducted by researchers from the University of Missouri, India?s Jawaharlal Nehru Medical College, the National Institutes of Health, and other institutions.
Bethesda, Md. ? Researchers from 12 institutions, including the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health (NIH), today announced the results of the first genome-wide linkage study of prostate cancer in African Americans. Using genetic markers, researchers identified several regions of the human genome that likely contain genes that, when altered, increase the risk of developing prostate cancer.
Bethesda, Md. ? The National Human Genome Research Institute (NHGRI), part of the National Institutes of Health (NIH), today announced the latest round of grant awards totaling more than $13.3 million to speed the development of innovative sequencing technologies that reduce the cost of DNA sequencing and expand the use of genomics in medical research and health care.
Caffeine has a stronger disruptive effect on daytime, catch-up sleep after a night of sleep deprivation.
Innocoll, Inc. announced that its wholly-owned subsidiary, Innocoll Pharmaceuticals, has received US 510k approval for CollaGUARD(TM), an advanced wound care product based on Innocoll’s proprietary CollaRx(TM) membrane technology. CollaGUARD is indicated for the management of superficial and deep wounds, including coverage of skin ulcers and temporary dermatoplasty in the case of lesion and burns. CollaGUARD has already received CE-mark approval for marketing in Europe.
Manhattan Pharmaceuticals, Inc. (Amex: MHA) today announced expansion of its oral Oleoyl-estrone (OE) clinical obesity program to include the morbidly obese. A new US Phase 2a clinical trial evaluating oral OE in morbidly obese male subjects will be initiated in October 2006. The morbidly obese population in the US is estimated to be 14 million people. OE is the Company’s orally administered product candidate in development for the treatment of obesity.
To prevent the infection of dengue virus, social awareness and control of mosquitoes is the foremost. The environment should be clean, water tanks and containers should be covered and mosquito nets should be used. If there is any fever, immediately consult qualified homoeopathic doctors or allopathic doctors, if required get hospitalized either in a clinic or hospital for proper observation and treatment.
The developmental oral therapy FTY720 (fingolimod) has demonstrated sustained benefits over two years in patients suffering from relapsing multiple sclerosis (MS), indicating that it could provide an important new option for treating this disabling neurological disease estimated to affect more than 2.5 million people worldwide.
Johnson & Johnson Pharmaceutical Research and Development, L.L.C. today announced that ceftobiprole, a novel cephalosporin(1) antibiotic in Phase III clinical trials, was found to be active against complicated skin infections caused by common, potentially deadly bacteria, including MRSA. These data were from two poster presentations given at the 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). These data also were highlighted by ICAAC. Ceftobiprole is being co-developed with Basilea Pharmaceutica, Ltd. through an exclusive worldwide collaboration.
Pfizer Inc said today that the European Commission has approved Champix(R) (varenicline), a novel pill for smoking cessation in adults. In addition, because smokers often need considerable support to quit successfully, Champix will be available with a patient support plan which smokers can customize to address their individual behavioral triggers as they try to quit smoking.